| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Nektar Therapeutics (NASDAQ: NKTR)
NKTR Technical Analysis
5
| As on 9th Jun 2023 NKTR SHARE Price closed @ 0.59 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 5.96 & Strong Sell for SHORT-TERM with Stoploss of 11.78 we also expect STOCK to react on Following IMPORTANT LEVELS. |
NKTRSHARE Price
| Open | 0.62 | Change | Price | % |
| High | 0.62 | 1 Day | -0.01 | -1.67 |
| Low | 0.59 | 1 Week | 0.01 | 1.72 |
| Close | 0.59 | 1 Month | -0.20 | -25.32 |
| Volume | 3027800 | 1 Year | -14.78 | -96.16 |
| 52 Week High 15.73 | 52 Week Low 0.58 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| NKTR Daily Charts |
NKTR Intraday Charts |
Whats New @ Bazaartrend |
NKTR Free Analysis |
|
|
NKTR Important Levels Intraday
| RESISTANCE | 0.65 |
| RESISTANCE | 0.63 |
| RESISTANCE | 0.62 |
| RESISTANCE | 0.61 |
| SUPPORT | 0.57 |
| SUPPORT | 0.56 |
| SUPPORT | 0.55 |
| SUPPORT | 0.53 |
NKTR Forecast April 2024
| 4th UP Forecast | 7.37 |
| 3rd UP Forecast | 5.2 |
| 2nd UP Forecast | 3.85 |
| 1st UP Forecast | 2.51 |
| 1st DOWN Forecast | -1.33 |
| 2nd DOWN Forecast | -2.67 |
| 3rd DOWN Forecast | -4.02 |
| 4th DOWN Forecast | -6.19 |
NKTR Weekly Forecast
| 4th UP Forecast | 5.31 |
| 3rd UP Forecast | 3.80 |
| 2nd UP Forecast | 2.86 |
| 1st UP Forecast | 1.93 |
| 1st DOWN Forecast | -0.75 |
| 2nd DOWN Forecast | -1.68 |
| 3rd DOWN Forecast | -2.62 |
| 4th DOWN Forecast | -4.13 |
NKTR Forecast2024
| 4th UP Forecast | 30.21 |
| 3rd UP Forecast | 20.71 |
| 2nd UP Forecast | 14.84 |
| 1st UP Forecast | 8.97 |
| 1st DOWN Forecast | -7.79 |
| 2nd DOWN Forecast | -13.66 |
| 3rd DOWN Forecast | -19.53 |
| 4th DOWN Forecast | -29.03 |
Nektar Therapeutics ( NASDAQ USA Symbol : NKTR )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
NKTR Business Profile
Nektar Therapeutics operates as a biopharmaceutical company. The company researches and develops pipeline of investigational medicines in oncology, immunology, and virology, as well as a portfolio of approved partnered medicines. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of non-small cell lung cancer and immuno-oncology; and phase 1B clinical trial to treat COVID-19.It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat locally advanced or metastatic solid tumor malignancies, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India. Address: 455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service